What is Avalyn Pharma?
Avalyn Pharma is a clinical-stage biopharmaceutical company dedicated to creating inhaled medicines for rare respiratory conditions such as Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILDs). These debilitating conditions are characterized by progressive lung scarring, leading to diminished lung function, reduced physical capacity, and a significant impact on quality of life and survival rates. Existing treatments offer symptomatic relief and slow disease progression but often come with considerable side effects that limit their efficacy and patient adherence. Avalyn's innovative approach focuses on delivering therapeutic agents directly to the lungs via inhalation, thereby minimizing systemic exposure and maximizing therapeutic benefit at the disease site. Their lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, designed for direct lung delivery and is currently Phase 2b-ready. Previous clinical studies have indicated AP01's potential to enhance both efficacy and safety compared to current standard-of-care therapies.
How much funding has Avalyn Pharma raised?
Avalyn Pharma has raised a total of $392.5M across 7 funding rounds:
Private Equity
$2.2M
Unspecified
$1.2M
Private Equity
$16.6M
Series A
$62M
Series B
$35.5M
Series C
$175M
Series D
$100M
Private Equity (2011): $2.2M, investors not publicly disclosed
Unspecified (2012): $1.2M, investors not publicly disclosed
Private Equity (2017): $16.6M, investors not publicly disclosed
Series A (2017): $62M featuring F-Prime Capital Partners, Edmond de Rothschild Investment Partners, RiverVest Venture Partners, Novo AS, and TPG Biotech
Series B (2020): $35.5M backed by PIVOTAL BIOVENTURE PARTNERS LLC, TPG Biotech, Novo Holdings, Norwest Venture Partners, RiverVest Venture Partners, and F-Prime Capital
Series C (2023): $175M with participation from Wellington Management, SR One, Eventide Asset Management, Rock Springs Capital, and Vida Ventures
Series D (2025): $100M led by Xontogeny, Eventide Asset Management, SR One, Vida Ventures, Catalio Capital Management, Wellington Management, Novo Holdings, Suvretta Capital Management, F-Prime Capital, TPG Biotech, Norwest Venture Partners, RiverVest Venture Partners, and Pivotal Healthcare Partners
Key Investors in Avalyn Pharma
Wellington Management
Wellington Management is a global, independent investment management firm providing institutional clients with portfolio management and research across various asset classes.
SR One
SR One is a transatlantic venture capital firm focused on early and growth-stage life sciences companies developing novel therapeutics, offering strategic and operational support.
Eventide Asset Management
Eventide Asset Management offers a range of mutual funds focused on integrity, impact, and outperformance, catering to various investor types with a values-based approach.
What's next for Avalyn Pharma?
The recent major strategic investment signifies a pivotal moment for Avalyn Pharma, likely enabling the company to accelerate its clinical development programs, particularly for its lead candidate AP01. This capital infusion is expected to support the progression through Phase 2b trials and potentially into later-stage development, bringing the company closer to addressing the significant unmet needs in IPF and ILD treatment. Furthermore, the backing from prominent investors suggests strong confidence in Avalyn's technology platform and therapeutic strategy. This funding will likely be instrumental in expanding the company's research and development capabilities, potentially exploring pipeline expansion, and preparing for future commercialization efforts. The company's focus on inhaled medicines for rare respiratory diseases positions it within a critical and growing segment of the biopharmaceutical market.
See full Avalyn Pharma company page
